Astellas Pharma Full Year 2025 Earnings: Beats Expectations

Simply Wall St · 06/22 00:11

Astellas Pharma (TSE:4503) Full Year 2025 Results

Key Financial Results

  • Revenue: JP¥1.91t (up 19% from FY 2024).
  • Net income: JP¥50.7b (up 198% from FY 2024).
  • Profit margin: 2.7% (up from 1.1% in FY 2024).
  • EPS: JP¥28.35 (up from JP¥9.51 in FY 2024).
earnings-and-revenue-growth
TSE:4503 Earnings and Revenue Growth June 22nd 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Astellas Pharma Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) also surpassed analyst estimates by 75%.

Looking ahead, revenue is expected to decline by 2.6% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 3.6%.

Performance of the Japanese Pharmaceuticals industry.

The company's shares are down 2.7% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 3 warning signs for Astellas Pharma (1 shouldn't be ignored!) that you need to be mindful of.